JAZZ
Jazz Pharmaceuticals plc
Key Financials
Revenue
$4.3B
↑ 4.9%
Net Income
$-356148000
↓ 163.6%
Gross Profit
$611.1M
↑ 10.1%
Operating Income
$-430240000
↓ 160.0%
Shareholders' Equity
$4.3B
↑ 5.5%
Cash & Equivalents
$1.4B
↓ 42.3%
EPS (Diluted)
$-5.84
↓ 167.5%
Total Assets
$11.7B
↓ 2.9%
Recent SEC Filings
| Form Type | Filed Date | Link |
|---|---|---|
| 4 | 4/3/2026 | View on SEC |
| 144 | 4/1/2026 | View on SEC |
| SCHEDULE 13G/A | 3/27/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
| 4 | 3/9/2026 | View on SEC |
Company Information
| Field | Value |
|---|---|
| Ticker | JAZZ |
| Company Name | Jazz Pharmaceuticals plc |
| CIK | 1232524 |
| Sector | Pharmaceutical Preparations |
| Industry | Large accelerated filer |
| Exchange | Nasdaq |
| SIC Code | 2834 |
| SIC Description | Pharmaceutical Preparations |
| Entity Type | operating |
| Fiscal Year End | 1231 |
| State of Incorporation | L2 |
| Phone | 353-1-634-7800 |